Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations. Uemoto Y, Lin CA, Wang B, Ye D, et al. Cancer Lett 2025;619:217668.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Uemoto Y, Lin CA, Wang B, Ye D, et al. Selective degradation of FGFR1/2 overcomes antiestrogen resistance in ER+ breast cancer with FGFR1/2 alterations. Cancer Lett 2025;619:217668.
PMID: 40127812